CN108992405A - A kind of preparation method of Doxazosin sustained release preparation - Google Patents

A kind of preparation method of Doxazosin sustained release preparation Download PDF

Info

Publication number
CN108992405A
CN108992405A CN201711109360.5A CN201711109360A CN108992405A CN 108992405 A CN108992405 A CN 108992405A CN 201711109360 A CN201711109360 A CN 201711109360A CN 108992405 A CN108992405 A CN 108992405A
Authority
CN
China
Prior art keywords
solution
doxazosin
sustained release
preparation
temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201711109360.5A
Other languages
Chinese (zh)
Inventor
刘丽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201711109360.5A priority Critical patent/CN108992405A/en
Publication of CN108992405A publication Critical patent/CN108992405A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides a kind of preparation method of Doxazosin sustained release preparation, and Doxazosin is dissolved in 95% ethyl alcohol, obtains solution A, hydroxypropylβ-cyclodextrin is added in solution A and mannitol obtains solution B；Polylactic acid and polyethylene glycol 200 are dissolved in acetone and obtain solution C, solution B and solution C are mixed into obtain solution D, solution D is transferred in magnetic stirring apparatus, continuous stirring solution D12 hours, solution D temperature is down to 0 DEG C~1 DEG C in 2 hours again and stands 12 hours, maintains solution D temperature at 0 DEG C~1 DEG C during standing.Solution D is heated after standing 12 hours, is continuously stirred when solution D temperature rises to 15 DEG C~18 DEG C, solution D temperature is controlled at 15 DEG C~18 DEG C when stirring, obtains Doxazosin sustained release preparation with low temperature spray drying legal system after continuously stirring 12 hours.Capsule material dosage of the present invention is moderate, and dry materials temperature is low, and obtained carrying medicine is uniform in size, and drug release is stablized, and has the characteristics that sustained release.

Description

A kind of preparation method of Doxazosin sustained release preparation
Technical field:
The present invention relates to a kind of pharmaceutical preparation of medicine-carrying polymer preparation more particularly to a kind of Doxazosin sustained release preparations Preparation method.
Background technique:
Hydroxypropylβ-cyclodextrin is a kind of ideal injection solubilizer and drug excipient in medical industry.It can be with The water solubility of insoluble drug is improved, increases medicine stability, improve drug bioavailability, the curative effect of medicament is made to increase or take Dosage is reduced, and adjustable or control drug rate of release reduces poisonous side effect of medicine.Can be used for oral drugs, injection, Mucoadhesive delivery system (including schneiderian membrane, rectum, cornea etc.), Transdermal absorption drug delivery system, lipophilicity targeted drug carrier.
Polylactic acid has tight security to human body, has good biocompatibility and biodegradability, is widely used In medicament slow release.Currently, the preparation method of polylactic acid drug bearing microsphere mainly has phase separation method, emulsion-solvent evaporation method, spray-on process Deng.
Doxazosin is long-acting alpha 1-receptor retarding agent.This product selectively acting 1 adrenocepter of α after section makes surrounding Blood vessel dilatation, peripheral vascular resistance are reduced and are reduced blood pressure.This product acts on the α 1- adrenal gland of prostate and bladder neck smooth muscle Plain receptor makes neck of urinary bladder, prostate, capsula prostatica smooth muscle relaxation, and urethra and bladder resistance lower, to mitigate prostate Symptoms of urethral blockage caused by hyperplasia.This product is mainly used for hyperpietic and benign prostatic hyperplasis.Doxazosin oral sustained release Constant slow release at a predetermined rate after preparation administration, can rapid delivery of pharmaceuticals rather than conventional formulation.With it is corresponding common Preparation, such as fast-release tablet, capsule, oral solution are compared, and the compliance of patient can be improved and increase curative effect of medication.The master of sustained release preparation Wanting advantage is the blood concentration peak valley phenomenon that can be reduced dosage frequency and avoid taking ordinary preparation appearance.Sustained release preparation can To keep blood concentration to stablize within the scope of effective blood drug concentration within the relatively long time, to improve the safety of drug Property.Doxazosin sustained release preparation mainly uses skeleton agent technology to produce at present, common ethyl cellulose, acrylic resin, lactose, The auxiliary materials such as microcrystalline cellulose.But the risk that drug release changes during there is burst release and storage with the dosage form that such technology produces, And supplementary product consumption is big, is unfavorable for taking orally.A kind of safe and effective, reliable in quality, high production efficiency are provided for clinic to this, auxiliary material is used Measure moderate, the stable Doxazosin sustained release preparation of drug release is necessary, in consideration of it, proposing the present invention.
Summary of the invention:
The technical problem to be solved by the present invention lies in overcoming the defects of the prior art, provides a kind of safe and effective, quality Reliably, high production efficiency, supplementary product consumption is moderate, the stable Doxazosin sustained release preparation and preparation method thereof of drug release.
The technical problems to be solved by the invention are realized using following technical scheme.
A kind of Doxazosin sustained release preparation, which is characterized in that the sustained release preparation by Doxazosin, hydroxypropylβ-cyclodextrin, Polylactic acid, mannitol, polyethylene glycol 200,95% ethyl alcohol and acetone composition.The Doxazosin sustained release preparation each component is by weight Amount containing 95% ethyl alcohol 140~160, contains hydroxypropylβ-cyclodextrin 100~120, contains mannitol 20~30 than containing Doxazosin 100, Containing acetone 100~140, contain polylactic acid 100~140, contain polyethylene glycol 200 20~40, the polylactic acid relative molecular weight is 5000~20000.
It is a further object to provide a kind of methods for being prepared into Doxazosin sustained release preparation, which is characterized in that The specific steps of this method are as follows:
1) Doxazosin is dissolved in 95% ethyl alcohol, obtains Doxazosin solution, is denoted as solution A；
2) hydroxypropylβ-cyclodextrin and mannitol are added in solution A, obtains solution B；
3) polylactic acid and polyethylene glycol are dissolved in acetone, obtain polylactic acid and polyethylene glycol 200 solution, is denoted as solution C；
4) solution B and solution C are mixed, obtains solution D；
5) solution D is transferred in magnetic stirring apparatus, controls the temperature of solution D at 15 DEG C~18 DEG C, continuous stirring solution D12 hours, then solution D temperature is down to 0 DEG C~1 DEG C in 2 hours and stands 12 hours, solution D temperature is maintained during standing At 0 DEG C~1 DEG C；
6) solution D for obtaining step 5 heats, and continuously stirs when solution D temperature rises to 15 DEG C~18 DEG C 12 hours, The control of solution D temperature is at 15 DEG C~18 DEG C when stirring；
7) solution D that step 6 obtains is obtained into Doxazosin sustained release preparation with low temperature spray drying legal system.
Doxazosin sustained release preparation of the invention is passed through to be released with the cumulative in vitro of commercially available same dosage form Doxazosin sustained release preparation Dose comparative study, it was demonstrated that Doxazosin sustained release preparation drug release of the invention is more stable, and slow-release function is more preferable.And it is prepared Method high production efficiency, capsule material dosage is moderate, and dry materials temperature is low, and obtained carrying medicine is uniform in size, and encapsulation rate is greater than 80%, drugloading rate is greater than 50%.
Detailed description of the invention
Curve a is the extracorporeal accumulating released medicine curve of 1 gained preparation of the embodiment of the present invention in Fig. 1, and curve b is commercially available identical The extracorporeal accumulating released medicine curve of dosage form Doxazosin sustained release preparation.In Fig. 1, abscissa is time (hour), and ordinate is Cumulative release amount (%).
Curve a is the extracorporeal accumulating released medicine curve of 2 gained preparation of the embodiment of the present invention in Fig. 2, and curve b is commercially available identical The extracorporeal accumulating released medicine curve of dosage form Doxazosin sustained release preparation.In Fig. 2, abscissa is time (hour), and ordinate is Cumulative release amount (%).
Curve a is the extracorporeal accumulating released medicine curve of 3 gained preparation of the embodiment of the present invention in Fig. 3, and curve b is commercially available identical The extracorporeal accumulating released medicine curve of dosage form Doxazosin sustained release preparation.In Fig. 3, abscissa is time (hour), and ordinate is Cumulative release amount (%).
Specific embodiment:
In order to be easy to understand the technical means, the creative features, the aims and the efficiencies achieved by the present invention, tie below Specific embodiment is closed, the present invention is further explained.
For the consistency of guarantee test result, the embodiment of the present invention has used the raw material of same batch, auxiliary material, and uses Consistent production technology prepares Doxazosin sustained release preparation.
Embodiment one:
1) 100g Doxazosin is dissolved in 140g95% ethyl alcohol, obtains Doxazosin ethanol solution, is denoted as solution A；
2) 100g hydroxypropylβ-cyclodextrin and 20g mannitol are added in solution A, obtains solution B；
3) 100g polylactic acid and 20g polyethylene glycol 200 are dissolved in 100g acetone, obtain polylactic acid and polyethylene glycol 200 is molten Liquid is denoted as solution C；
4) solution B and solution C are mixed, obtains solution D；
5) solution D is transferred in magnetic stirring apparatus, controls the temperature of solution D at 15 DEG C~18 DEG C, continuous stirring solution D12 hours, then solution D temperature is down to 0 DEG C~1 DEG C in 2 hours and stands 12 hours, solution D temperature is maintained during standing At 0 DEG C~1 DEG C；
6) solution D for obtaining step 5 heats, and continuously stirs when solution D temperature rises to 15 DEG C~18 DEG C 12 hours, The control of solution D temperature is at 15 DEG C~18 DEG C when stirring；
7) solution D that step 6 obtains is obtained into Doxazosin sustained release preparation, the temperature of spray drying with low temperature spray drying legal system Degree control is at 55 DEG C, nozzle diameter: 0.5mm, vacuum degree: 0.03MPA, flow: 500ml/ hours.
Sample obtained by low temperature spray drying is taken, it is 81.08% that gained sample, which measures encapsulation rate, carrying drug ratio 50.16%, body Outer release experiment proves that this preparation energy slow release Doxazosin, Doxazosin are finally discharged up to 90% or more, sees Fig. 1.
Embodiment two:
1) 100g Doxazosin is dissolved in 150g95% ethyl alcohol, obtains Doxazosin ethanol solution, is denoted as solution A；
2) 110g hydroxypropylβ-cyclodextrin and 25g mannitol are added in solution A, obtains solution B；
3) 130g polylactic acid and 30g polyethylene glycol 200 are dissolved in 130g acetone, obtain polylactic acid and polyethylene glycol 200 is molten Liquid is denoted as solution C；
4) solution B and solution C are mixed, obtains solution D；
5) solution D is transferred in magnetic stirring apparatus, controls the temperature of solution D at 15 DEG C~18 DEG C, continuous stirring solution D12 hours, then solution D temperature is down to 0 DEG C~1 DEG C in 2 hours and stands 12 hours, solution D temperature is maintained during standing At 0 DEG C~1 DEG C；
6) solution D for obtaining step 5 heats, and continuously stirs when solution D temperature rises to 15 DEG C~18 DEG C 12 hours, The control of solution D temperature is at 15 DEG C~18 DEG C when stirring；
7) solution D that step 6 obtains is obtained into Doxazosin sustained release preparation, the temperature of spray drying with low temperature spray drying legal system Degree control is at 55 DEG C, nozzle diameter: 0.75mm, vacuum degree: 0.035MPA, flow: 700ml/ hours.
Sample obtained by low temperature spray drying is taken, it is 80.40% that gained sample, which measures encapsulation rate, carrying drug ratio 50.26%, body Outer release experiment proves that this preparation energy slow release Doxazosin, Doxazosin are finally discharged up to 90% or more, sees Fig. 2.
Embodiment three:
1) 100g Doxazosin is dissolved in 160g95% ethyl alcohol, obtains Doxazosin ethanol solution, is denoted as solution A；
2) 120g hydroxypropylβ-cyclodextrin and 30g mannitol are added in solution A, obtains solution B；
3) 140g polylactic acid and 40g polyethylene glycol 200 are dissolved in 140g acetone, obtain polylactic acid and polyethylene glycol 200 is molten Liquid is denoted as solution C；
4) solution B and solution C are mixed, obtains solution D；
5) solution D is transferred in magnetic stirring apparatus, controls the temperature of solution D at 15 DEG C~18 DEG C, continuous stirring solution D12 hours, then solution D temperature is down to 0 DEG C~1 DEG C in 2 hours and stands 12 hours, solution D temperature is maintained during standing At 0 DEG C~1 DEG C；
6) solution D for obtaining step 5 heats, and continuously stirs when solution D temperature rises to 15 DEG C~18 DEG C 12 hours, The control of solution D temperature is at 15 DEG C~18 DEG C when stirring；
7) solution D that step 6 obtains is obtained into Doxazosin sustained release preparation with low temperature spray drying legal system,
The temperature of spray drying is controlled at 60 DEG C, and nozzle diameter: 1mm, vacuum degree: 0.04MPA, flow: 1000ml/ is small When.
Sample obtained by low temperature spray drying is taken, it is 81.18% that gained sample, which measures encapsulation rate, carrying drug ratio 51.07%, body Outer release experiment proves that this preparation energy slow release Doxazosin, Doxazosin are finally discharged up to 90% or more, sees Fig. 3.
The basic principles, main features and advantages of the present invention have been shown and described above.The technology of the industry For personnel it should be appreciated that the present invention is not limited to the above embodiments, described in the above embodiment and specification is only the present invention Preference, be not intended to limit the invention, without departing from the spirit and scope of the present invention, the present invention also has various Changes and improvements, these changes and improvements all fall within the protetion scope of the claimed invention.The claimed scope of the invention is by institute Attached claims and its equivalent thereof.

Claims (5)

1. a kind of preparation method of Doxazosin sustained release preparation, it is characterised in that the Doxazosin sustained release preparation is by sandy azoles Piperazine, hydroxypropylβ-cyclodextrin, polylactic acid, mannitol, polyethylene glycol 200,95% ethyl alcohol, acetone composition.
2. the preparation method of Doxazosin sustained release preparation as described in claim 1, it is characterised in that the steps include:
1) Doxazosin is dissolved in 95% ethyl alcohol, obtains Doxazosin solution, is denoted as solution A；
2) hydroxypropylβ-cyclodextrin and mannitol are added in solution A, obtains solution B；
3) polylactic acid and polyethylene glycol are dissolved in acetone, obtain polylactic acid and polyethylene glycol 200 solution, is denoted as solution C；
4) solution B and solution C are mixed, obtains solution D；
5) solution D is transferred in magnetic stirring apparatus, controls the temperature of solution D at 15 DEG C~18 DEG C, continuous stirring solution D12 is small When, then solution D temperature is down to 0 DEG C~1 DEG C in 2 hours and stands 12 hours, maintain solution D temperature at 0 DEG C during standing ~1 DEG C；
6) solution D for obtaining step 5 heats, and continuously stirs when solution D temperature rises to 15 DEG C~18 DEG C 12 hours, stirs When solution D temperature control at 15 DEG C~18 DEG C；
7) solution D that step 6 obtains is obtained into Doxazosin sustained release preparation with low temperature spray drying legal system.
3. Doxazosin sustained release preparation each component as claimed in claim 1 or 2 contains Doxazosin 100 by weight, contain 95% Ethyl alcohol 140~160 contains hydroxypropylβ-cyclodextrin 100~120, contains mannitol 20~30, contains acetone 100~140, contains polylactic acid 100~140, contain polyethylene glycol 200 20~40.
4. the preparation method of Doxazosin sustained release preparation as claimed in claim 1 or 2, it is characterised in that opposite point of polylactic acid Son amount is 5000~20000.
5. the preparation method of Doxazosin sustained release preparation as claimed in claim 3, it is characterised in that the temperature of low temperature spray drying Degree is 55 DEG C~60 DEG C, and nozzle diameter is 0.5mm~1mm, and hothouse vacuum degree is 0.03MPA~0.04MPA, solution D flow It is 500ml/ hours~1000ml/ hours.
CN201711109360.5A 2017-11-11 2017-11-11 A kind of preparation method of Doxazosin sustained release preparation Withdrawn CN108992405A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711109360.5A CN108992405A (en) 2017-11-11 2017-11-11 A kind of preparation method of Doxazosin sustained release preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201711109360.5A CN108992405A (en) 2017-11-11 2017-11-11 A kind of preparation method of Doxazosin sustained release preparation

Publications (1)

Publication Number Publication Date
CN108992405A true CN108992405A (en) 2018-12-14

Family

ID=64573175

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201711109360.5A Withdrawn CN108992405A (en) 2017-11-11 2017-11-11 A kind of preparation method of Doxazosin sustained release preparation

Country Status (1)

Country Link
CN (1) CN108992405A (en)

Similar Documents

Publication Publication Date Title
Chen et al. Self-implanted tiny needles as alternative to traditional parenteral administrations for controlled transdermal drug delivery
CN109010312A (en) A kind of preparation method of sustained-release theophylline preparation
CN108992420A (en) A kind of preparation method of salbutamol sustained release preparation
CN104825416A (en) Disulfiram implant and preparation method thereof
CN108992405A (en) A kind of preparation method of Doxazosin sustained release preparation
CN108992408A (en) A kind of preparation method of body of Pramipexole dihydrochloride sustained release preparation
CN108992427A (en) A kind of preparation method of Flurbiprofen sustained release preparation
CN108992409A (en) A kind of preparation method of metformin hydrochloride slow release preparation
CN109010316A (en) A kind of preparation method of vitamin B 6 sustained release preparation
CN108992394A (en) A kind of preparation method of pseudoephedrine hydrochloride slow release preparation
CN109010313A (en) A kind of preparation method of alfuzosin hydrochloride sustained release preparation
CN101249082B (en) Preparation of acidum citricum tamoxifen polylactic acid-glycolic co-polymer microballoons
CN108992423A (en) A kind of preparation method of tamsulosin hydrochloride sustained release preparation
CN105193764A (en) Agomelatine solid dispersoid and preparation method thereof
CN108992424A (en) A kind of preparation method of nevirapine sustained release preparation
CN108992426A (en) A kind of preparation method of 9-hydroxy-risperidone sustained release preparation
CN109010277A (en) A kind of preparation method of oxycodone hydrochloride sustained release preparation
CN109010315A (en) A kind of preparation method of Etodolac sustained release preparation
CN108992428A (en) A kind of preparation method of felodipine sustained-release preparation
CN109010314A (en) A kind of preparation method of indapamide slow release preparation
CN108992406A (en) A kind of preparation method of ropinirole hydrochloride sustained release preparation
CN108992421A (en) A kind of preparation method of methylphenidate hydrochloride sustained release preparation
CN108992407A (en) A kind of preparation method of aminophylline sustained release preparation
CN109010279A (en) A kind of preparation method of venlafaxine hydrochloride sustained-release preparation
CN108992461A (en) A kind of preparation method of potassium chloride sustained release preparation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20181214